My Tiny Feed

elmundo.es

Alzheimer's Research: Advancements and Challenges

This article discusses the latest advancements and challenges in Alzheimer's drug development, focusing on various therapeutic targets, drug repurposing, and the regulatory landscape.

Read original article in Spanish

Spanish

Spain

HealthDevelopmentResearchTreatmentPharmaceuticalsAlzheimer's

EmaPhrmaNiceSenAce Alzheimer Center Barcelona

Raquel Sánchez ValleXavier MoratóMercè Boada

Are there any examples of drug repositioning or repurposing for Alzheimer's treatment?: Besides biologicals, several drugs repurposed from other disease treatments (obesity, erectile dysfunction, malaria) are being tested for Alzheimer's, such as semaglutide and mirodefanil. These demonstrate the exploration of diverse therapeutic avenues.
What are the main findings regarding lecanemab and donanemab in the treatment of Alzheimer's?: Lecanemab and donanemab, monoclonal antibodies targeting amyloid beta plaques in the brain, have shown a correlation between plaque reduction and slowed cognitive decline. However, the EMA denied approval for lecanemab due to modest efficacy and potential risks of ARIA.
What are some alternative therapeutic targets and approaches being explored beyond amyloid beta?: Several other biological therapies targeting amyloid beta are in development, along with treatments focusing on tau protein, a different key factor in Alzheimer's disease. These include monoclonal antibodies and antisense oligonucleotides.
What is the anticipated future direction of Alzheimer's treatment, considering current research?: Combination therapies targeting amyloid beta, tau protein, and inflammation are seen as the future for Alzheimer's treatment, given the disease's complexity. Early administration of these combinations is considered crucial.
What are some of the key challenges and considerations regarding the approval and adoption of new Alzheimer's drugs?: The EMA's rejection of lecanemab highlights the challenges of balancing efficacy and safety in Alzheimer's drug development. Future approvals will likely favor orally administered drugs with fewer adverse effects and repurposed medications.

Jan 23, 10:08

Trump Launches \$500 Billion AI Project to Cure Cancer

President Trump launched Project Stargate, a \$500 billion AI-driven initiative to develop personalized mRNA cancer vaccines, aiming to detect and treat early-stage cancers through AI-powered blood tests and rapid vaccine production within 48 hours, despite concerns about public and political resistance.

Jan 23, 01:10

Microplastics Linked to Brain Blood Clots, Raising Dementia and Stroke Risks

A Peking University study reveals microplastics in the brain trigger immune responses, causing blood clots that may lead to stroke, depression, and possibly dementia; further research is needed.

Jan 23, 01:10

Rare Gene Mutation Linked to Late-Onset Alzheimer's

A study of an Italian family with six members affected by late-onset Alzheimer's disease reveals a rare mutation in the GRIN2C gene as a probable cause, offering a significant advancement in understanding the disease's genetic basis.

Jan 23, 01:10

Danish Medical Data Breach Exposes 130,000 Patient Records

A data breach at a Danish medical practice group exposed the sensitive information of 130,000 patients, including names, addresses, national identification numbers, and treatment protocols, nearly a month after the initial cyberattack, sparking public outrage over the delayed notification.